An Evaluation of Two Schedules of VP-16 and Adriamycin in Patients with Advanced Breast Cancer

Abstract
A phase II study utilizing VP-16 and adriamycin in a randomized fashion tested the concept of synchronization of the drugs in treatment of metastatic breast cancer. Although there was a trend in median survival following the synchronized schedule, there was no significant difference in survival or progression-free intervals. The concept of synchronization was not established.

This publication has 0 references indexed in Scilit: